Sidney Kimmel

AccessHope Secures $33 Million in Series B Funding to Expand Access to Leading Cancer Expertise

Retrieved on: 
Monday, April 22, 2024
UnitedHealth Group, Cancer, Emory Healthcare, City, Sidney Kimmel, Johns Hopkins, Business development, National Cancer Institute, Winship Cancer Institute, Growth, Policy, Patient, Blackstone Inc., Acquisition, NCI, Medicare, Emory University, Health, Dana–Farber Cancer Institute, Pharmaceutical industry

DUARTE, Calif., April 22, 2024 /PRNewswire/ -- AccessHope, LLC, a company changing the way leading-edge cancer expertise is delivered, today announced that it has raised $33 million in a Series B round of funding from City of Hope, one of the largest cancer research and treatment organizations in the United States. AccessHope's next phase of growth as a stand-alone company will include product and technology development, oncology network expansion and entering new markets, such as health plans, Medicare and government organizations.

Key Points: 
  • To lead its transformation into a commercial business, AccessHope appointed seasoned healthcare, payer and investment veteran Bradley Kreick as its new CEO.
  • Kreick, who has served on the AccessHope board since 2023, brings 30 years of experience leading companies through periods of significant growth.
  • "AccessHope was founded with the mission of bringing cutting-edge cancer care knowledge to the places and people who need it most.
  • Through these collaborations, AccessHope members now have access to expertise from more than 350 of the world's top oncologists, covering all cancer types and stages.

Giant Food Releases Fourth Annual Better Neighbor Report

Retrieved on: 
Wednesday, April 10, 2024
Giant, Sidney Kimmel, Woman, Annual report, Giant Food, Food

LANDOVER, Md., April 10, 2024 /PRNewswire/ -- Giant Food, the leading greater Washington, D.C. regional grocery chain, today announces the release of its fourth annual Better Neighbor Report, which spotlights the company's efforts to serve its customers, associates, and communities. The fourth annual report details Giant's efforts in 2023 and illustrates the retailer's continued commitments to being a Better Neighbor, a Better Place to Shop, and a Better Place to Work.

Key Points: 
  • The report details the retailer's dedication to associates, local partners, and communities.
  • LANDOVER, Md., April 10, 2024 /PRNewswire/ -- Giant Food , the leading greater Washington, D.C. regional grocery chain, today announces the release of its fourth annual Better Neighbor Report, which spotlights the company's efforts to serve its customers, associates, and communities.
  • The fourth annual report details Giant's efforts in 2023 and illustrates the retailer's continued commitments to being a Better Neighbor, a Better Place to Shop, and a Better Place to Work.
  • "The annual Better Neighbor Report allows us to reflect on the many positive changes we've created in our company – online, and at our stores and distribution facilities - for our associates, our customers, and within our community," said Ira Kress, President of Giant Food.

iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)

Retrieved on: 
Tuesday, February 27, 2024
MSK, University, Research, DKFZ, Quality of life, Sidney Kimmel, Radiology, National academy, ICAD, Faculty, Molecular Pharmacology, Translation, Trustee, Johns Hopkins University, NAM, Biomedical sciences, Book, Medical device

Dr. Hricak is a renowned radiologist and researcher with over 40 years of experience in the field.

Key Points: 
  • Dr. Hricak is a renowned radiologist and researcher with over 40 years of experience in the field.
  • Dr. Hricak is a member of the National Academy of Medicine and received the David Rall Medal, the NAM award for distinguished leadership.
  • The hallmark of her academic career has been developing, translating, and disseminating new diagnostic imaging techniques, primarily for genitourinary cancers.
  • “We are thrilled to welcome Dr. Hricak to the iCAD Board of Directors,” said Dana Brown, President, CEO, and Chairman of the Board.

Independent Research Data On Hepatic Artery Infusion (HAI) Therapy Tp Be Featured At ASCO GI Cancer Symposium

Retrieved on: 
Tuesday, January 16, 2024
Neoplasm, Patient, PST, Research, Local, Pancreas, ASCO, Poster, Rectum, Sidney Kimmel, Johns Hopkins, Cholangiocarcinoma, Hepatic artery proper, HAI, Liver disease, Liver, FDA, Progress, CRC, Colorectal cancer, Physician, Pharmaceutical industry

BOSTON, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Intera Oncology, maker of the only FDA-approved implantable pump for Hepatic Artery Infusion (HAI) therapy, announces independent research on HAI therapy will be presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI) January 18-20 in San Francisco, California, USA.

Key Points: 
  • BOSTON, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Intera Oncology, maker of the only FDA-approved implantable pump for Hepatic Artery Infusion (HAI) therapy, announces independent research on HAI therapy will be presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI) January 18-20 in San Francisco, California, USA.
  • Researchers from several top academic medical institutions will present their findings related to HAI therapy through live presentations, oral abstracts, and posters at the symposium.
  • HAI therapy is a powerful treatment for patients with colorectal cancer (CRC) that has spread to the liver and those with intrahepatic cholangiocarcinoma (iCCA).
  • To learn more about evidence supporting the use of HAI therapy, visit Intera Oncology at Exhibitor Booth #4 at #GI24.

OneOncology Appoints Ian Flinn, MD, PhD as Chief Scientific Officer

Retrieved on: 
Monday, November 20, 2023
Research, Johns Hopkins, Bone marrow, Association rule learning, Patient, St Vincent's Hospital, Sydney, Hematology, Sarah Cannon Research Institute, SCRI, Sidney Kimmel, Doctor of Philosophy, Management, Pharmaceutical industry, MD

NASHVILLE, Tenn., Nov. 20, 2023 /PRNewswire/ -- OneOncology, the fastest-growing national platform for independent oncology practices, has appointed Ian Flinn, MD, PhD, as Chief Scientific Officer.

Key Points: 
  • NASHVILLE, Tenn., Nov. 20, 2023 /PRNewswire/ -- OneOncology, the fastest-growing national platform for independent oncology practices, has appointed Ian Flinn, MD, PhD, as Chief Scientific Officer.
  • OneOncology appoints Ian Flinn, MD, PhD, as Chief Scientific Officer to oversee OneR, OneOncology's research network.
  • Dr. Flinn will also service as Chief Scientific Officer at Tennessee Oncology.
  • "Dr. Flinn will be a valuable resource for our practice partners to advance their clinical trial programs," said Davey Daniel, MD, Chief Medical Officer, OneOncology.

New Resource from National Comprehensive Cancer Network Breaks the Silence on Common but Lesser-Known Cause of Cancer Deaths

Retrieved on: 
Thursday, September 7, 2023
Pancreatic cancer, Sidney Kimmel, VTE, Surgeon, Thrombus, Journal of the National Comprehensive Cancer Network, Pulmonary embolism, Neoplasm, Multiple myeloma, Graft-versus-host disease, Risk assessment, Chest pain, National Comprehensive Cancer Network, Thrombosis, Cardiology, Immunotherapy, Visit, NCCN, Radiology, Vomiting, Pancreatic serous cystadenoma, Anticoagulant, Back pain, Pharmacist, Estate (law), Coronary thrombosis, Guideline, Patient, Amazon (company), Sidney Kimmel Comprehensive Cancer Center, Risk, Swelling, Anemia, Disease, FACS, Nausea, Johns Hopkins, Research, Health, Death, Red, Education, Caregiver, Content, Birth control, Cancer, MD

PLYMOUTH MEETING, Pa., Sept. 7, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN®) today announced the publication of a new supportive care patient guideline focused on preventing and treating cancer-associated blood clots, also known as venous thromboembolism (VTE). Research shows that people with cancer are nine times more likely to experience blood clots than those without cancer. Blood clots are a leading cause of death for people with cancer, second only to the direct effects of the cancer itself.1,2

Key Points: 
  • Research shows that people with cancer are nine times more likely to experience blood clots than those without cancer.
  • Blood clots are a leading cause of death for people with cancer, second only to the direct effects of the cancer itself.1,2
    Research shows that people with cancer are nine times more likely to experience blood clots than those without cancer.
  • "Cancer is a strong risk factor for developing a blood clot, and thrombosis is the second leading cause of death in patients with cancer.
  • Preventing and treating blood clots is also discussed in several relevant disease-specific NCCN patient guidelines, including for pancreatic cancer, multiple myeloma, and myeloproliferative neoplasms.

Break Through Cancer, A New Research Consortium, Names First Class of Scientists Designated as Catalysts for Innovation and Collaboration

Retrieved on: 
Tuesday, April 25, 2023
The Ride to Conquer Cancer, Sidney Kimmel, Sreyashi Jhumki Basu, GBM, Research group, Ovarian cancer, Pancreatic cancer, Cancer, Research, Koch Institute, MIT, CD73, Genomics, The Institute, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Associate, Science, Physician, Sidney Kimmel Comprehensive Cancer Center, University, Escape Room, Drug development, Knowledge, Koch Institute for Integrative Cancer Research, TeamLab (art collective), Johns Hopkins, Break, Tumor microenvironment, Nanobiotechnology, Vaccine, Medical imaging

CAMBRIDGE, Mass., April 25, 2023 /PRNewswire/ -- Break Through Cancer, a foundation designed to find new solutions to some of the most intractable challenges in cancer, has named four individuals as Break Through Cancer Scientists—Neelkanth Bardhan, Sreyashi Basu, Paola A. Guerrero, and Thomas R. Pisanic II. They are professional scientists who cooperate on and lead projects with the skills, knowledge, and insights to maximize the impact of the cross-institutional collaboration.

Key Points: 
  • They are professional scientists who cooperate on and lead projects with the skills, knowledge, and insights to maximize the impact of the cross-institutional collaboration.
  • The Break Through Cancer Scientists were carefully selected based on their expertise in early diagnostics, single cell genomics data and materials science, and specific types of cancer.
  • "These newly named Break Through Cancer Scientists have cultivated stellar reputations and demonstrated outstanding success in working across scientific disciplines to establish a collaborative environment.
  • A Research Group Leader at The University of Texas MD Anderson Cancer Center's Pancreatic Cancer Research Center, Paola leads innovative research on patient-derived models and biospecimens.

Century Therapeutics Announces Leadership Changes

Retrieved on: 
Wednesday, April 12, 2023
Georgia Tech, Johns Hopkins University, National Science Board, Roche, Biochemistry, Strategic management, Research and development, Iran National Science Foundation, Patient, Cell, Chemical engineering, GSK plc, The Jacob Rader Marcus Center of the American Jewish Archives, IPSC, Merck & Co., Rensselaer Polytechnic Institute, Corporation, Growth, Urology, Vaccine, GSK, Duke University, Business, CAR, Science, Education minister, Century, Juno Therapeutics, Amicus Therapeutics, Therapy, Industrial, Sidney Kimmel, Commercialization, Case Western Reserve University, AstraZeneca, Executive Committee, Marcus Center, Johns Hopkins School of Medicine, Ewing Marion Kauffman Foundation, Management, Pharmaceutical industry, Limited, Celgene, Research, Rutgers University, Medicine

PHILADELPHIA, April 12, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Greg Russotti, Ph.D., as ad-interim Chief Executive Officer, effective April 11, 2023. Dr. Russotti, who has served as the Company’s Chief Technology Officer since January 2020, is succeeding Lalo Flores, Ph.D., who has stepped down as Chief Executive Officer and as a member of the Company’s Board of Directors to pursue other opportunities. In addition, effective April 11, 2023, Michael C. Diem, M.D., was promoted to the role of Chief Financial Officer, and Hy Levitsky, M.D., assumed his prior role as President of Research and Development.

Key Points: 
  • “Lalo has played a key role in advancing Century, a premier cell therapy company, to where it is today.
  • Prior to Celgene, he held various leadership roles at Merck Research Laboratories, developing vaccines and monoclonal antibodies for clinical and commercial manufacturing.
  • Prior to joining Century, he was Senior Vice President of Business and Corporate Development at Amicus Therapeutics, and prior to that, he held a similar role at Aevi Genomic Medicine.
  • He currently serves as a member of the Board of Directors of Replimune, Prokarium, and Carisma Therapeutics.

Cancer Nutrition Consortium Releases Cookbook to Provide Cancer Patients with Best Nutrition Possible

Retrieved on: 
Monday, January 9, 2023
Cancer, Taste, Johns Hopkins, Patient, Sidney Kimmel Comprehensive Cancer Center, Food, Research, Ohio State University, Knowledge, Mayo Clinic Cancer Center, Terminology of the Low Countries, Digestion, Ohio State University Wexner Medical Center, Radiation, Nausea, Treatment, Physician, Impact, CNC, Appetite, Sidney Kimmel, Life, Diagnosis, Dana, Collection, Dietary supplement, Pharmaceutical industry, Cooking, Cookbook

BOSTON, Jan. 9, 2023 /PRNewswire-PRWeb/ -- Food is one of the basic necessities of life.

Key Points: 
  • Cookbook is a collection of nutrition-focused recipes, based on clinical research, designed to give cancer patients the best nutrition possible while facing challenges during chemotherapy, radiation, and surgical treatments.
  • According to a 2015 study, "The Impact of Cancer Treatment on the Diets & Food Preferences of Patients Receiving Outpatient Treatment" , one of the biggest challenges for people undergoing cancer treatment is getting proper nutrition.
  • Cooking Through Treatment is produced and published by the Cancer Nutrition Consortium (CNC), a non-profit that works to promote and better understand the importance of nutrition for positive medical outcomes for patients during cancer treatment and recovery.
  • The Cancer Nutrition Consortium, Inc. is approved as a tax-exempt, not-for-profit 501(c)(3) corporation organized in the State of Florida.

Think tank’ develops proposals to leverage precision medicine to improve cholangiocarcinoma patient outcomes

Retrieved on: 
Tuesday, October 25, 2022
Quality of life, Method, Lung, Caregiver, Cholangiocarcinoma, Stent, Sidney Kimmel, Disease, Therapy, Bile duct, Neoplasm, Bile, Diagnosis, Science, List of American Medical Association journals, Education, JAMA Network Open, Foundation, Patient, Biology, Primary sclerosing cholangitis, Research, Colonoscopy, Sidney Kimmel Comprehensive Cancer Center, Precision medicine, Cancer, Gallbladder, Roy Taylor (scientist), Incidence, Awareness, Liver, Survival, GLOBE, Smoker, CCA, PSC, CCF, Cohort study, Leadership, Medical device, Medical imaging, Pharmaceutical industry, Vaccine

This effort, made possible by generous philanthropic donations to the Cholangiocarcinoma Foundation , was the first of its kind in the cholangiocarcinoma (CCA) field.

Key Points: 
  • This effort, made possible by generous philanthropic donations to the Cholangiocarcinoma Foundation , was the first of its kind in the cholangiocarcinoma (CCA) field.
  • The primary themes precision prevention, early detection, and precision therapeutics reflected areas of urgency and opportunity for improving outcomes for people impacted by CCA.
  • Cholangiocarcinoma is a type of cancer that forms in the slender tubes called bile ducts that carry the digestive fluid bile.
  • Its mission is to find a cure for cholangiocarcinoma (bile duct cancer) and improve the quality of life for patients.